The Health Resources and Services Administration has issued a warning to Sanofi over its plan to implement a new credit model for sales of certain covered outpatient drugs, threatening to remove the pharmaceutical company from the 340B Drug Pricing Program if the proposal is not halted.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
